Friday, 19 Oct 2018

You are here

Predictive Risk Factors for Uveitis in JIA

Researchers from Germany have studied a large cohort of juvenile idiopathic arthritis (JIA) patients and shown that JIA disease activity scores and laboratory biomarkers could be used to better define the group of JIA patients at high risk of uveitis onset.

They studied 964 JIA kids enrolled within the first year of their JIA diagnosis. Of these, two-thirds were female, 54.2% were antinuclear antibody [ANA] positive, and their mean age at onset was 7.1 years.

Uveitis occurred in 133 patients (13.7%).  Predictors of uveitis included younger age at onset and ANA positivity (P < 0.001). 

Prevention of uveitis was observed with methotrexate (hazard ratio [HR] 0.18 [95% confidence interval (95% CI) 0.12–0.29], P < 0.001), etanercept (HR 0.10; 0.04–0.23) or adalimumab (HR 0.09; 0.01–0.61).

Other significant lab and biomarker predictors of uveitis included an elevated erythrocyte sedimentation rate at baseline (HR 2.36), moderate or high disease activity during (HR 4.30), and S100A12 levels ≥250 ng/ml at baseline (HR 2.10).

Uveitis may be a serious vision‐threatening complication of JIA and these data may bolster future prevention strategies in newly diagnosed JIA.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Elder Rheumatoids Less Likely to Receive Biologics

Multiple studies have shown that elderly rheumatoid arthritis (RA) patients tend to be under-treated and receive DMARD therapies less often than younger RA patients. Now a VAMC study shows that the elderly are less likely to receive biologic agents yet are as likely to be subjected to glucocorticoid use.

Long-Term Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis

Only inhibitors of IL-1 (canakinumab) and IL-6 (tocilizumab) are FDA approved for use in children with systemic onset juvenile idiopathic arthritis (sJIA). Now, long-term data from the extension studies from two phase III studies shows that canakinumab yields long-term improvements with reduced glucocorticoid dosing with no new safety findings with long-term use.

Defining Refractory Rheumatoid Arthritis

Researchers from the British Society for Rheumatology Biologics (BSRBR) set out to define under what circumstances will rheumatoid arthritis (RA) patients manifest biologic disease-modifying antirheumatic drugs (bDMARDs) refractory disease.

Using the patients from the BSRBR Register (2001 to 2014) they defined patients as bDMARD refractory when they initiated their third class of bDMARD.

Venous Thromboembolism Increased with Rheumatoid Arthritis, Not with TNF Inhibition

Venous thromboembolism (VTE) is a common adverse event throughout medicine and includes both pulmonary embolism (PE) and deep vein thrombosis (DVT).   The cost of diagnosing a thromboembolic event is approximately $4000 - $5550, while the annual cost of treating one case of VTE is between $17,000 and $19,000. The impact of VTE is substantial. 

What Works in Undifferentiated Arthritis Patients

There is a paucity of guidance on how to best manage patients who may be at risk for rheumatoid arthritis (e.g., first degree rela